Key facts
- BioCopy’s last known valuation is $88.1M (Mar 2025).
- It has raised $11.0M; the latest was Seed Round ($8.8M) in Mar 2025.
- Notable investors include EASME - EU Executive Agency for SMEs, The University of Freiburg.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for BioCopy
- ·The full record, as it builds
Funding rounds
No funding rounds for BioCopy are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioCopy
Developer of a biomolecule copying technology designed for the production and replication of microarrays. The company's technology provides a shortcut to navigate the complexity of the immune system for future tumor and autoimmune therapy which can be applied in diagnostics, vaccine development, as well as lead and hit screening, enabling clients to copy biomolecules analogous to a photocopier.
- Sector
- Healthcare
- HQ
- Basel, Switzerland
- Founded
- 2016
- Employees
- 35
- Website
- biocopy.com/
- Ownership
- Privately Held (backing)
BioCopy doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioCopy shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioCopy in its N-PORT filings yet. We sweep new filings monthly.